How InteliCare’s $1.8M Raise Counters $834K Quarterly Cash Burn
InteliCare Holdings reported a $834,000 operating cash outflow for Q3 2025 but bolstered its balance sheet with a $1.8 million capital raise, positioning itself to sustain operations over the coming quarters.
- Net operating cash outflow of A$834,000 for the quarter
- Raised approximately A$1.827 million in first tranche of capital raise
- Second tranche of $173,000 pending shareholder approval
- Cash and equivalents at quarter end stood at A$1.752 million
- Secured A$901,000 funding facility against FY26 R&D claim
Quarterly Cash Flow Snapshot
InteliCare Holdings Limited has disclosed a net operating cash outflow of A$834,000 for the quarter ended 30 September 2025, reflecting ongoing investment in its health technology operations. Despite the cash burn, the company ended the quarter with a solid cash balance of A$1.752 million, providing a buffer as it navigates its growth trajectory.
Capital Raise Strengthens Liquidity
In a strategic move to shore up its finances, InteliCare successfully completed the first tranche of a capital raise announced in mid-September, securing approximately A$1.827 million. The second tranche, which would add around A$173,000, awaits shareholder approval. This injection of funds is critical as the company manages its operating costs and invests in product development and marketing.
Managing Operating Costs and Funding
The company’s operating expenses remain elevated, with significant outflows in staff costs, administration, and marketing. However, InteliCare is actively working to reduce operating cash flows while maintaining current levels over the next two quarters. Additionally, the company holds a secured funding facility of A$901,000, backed by its FY26 research and development tax incentive claim, which adds a layer of financial flexibility.
Outlook and Operational Continuity
InteliCare’s management expresses confidence in its ability to continue operations and meet business objectives, supported by available cash, the recent capital raise, and ongoing evaluation of further funding options. The company’s approach suggests a cautious but proactive stance toward sustaining growth and navigating the challenges of the health technology sector.
Bottom Line?
InteliCare’s recent capital raise provides breathing room, but upcoming shareholder approval and cost management will be pivotal for its financial health.
Questions in the middle?
- Will the second tranche of the capital raise secure shareholder approval as planned?
- What specific measures is InteliCare implementing to reduce operating cash outflows?
- Are there plans for additional financing beyond the current secured facility and placement?
